News

To meet the growing needs of the market, Cardinal Health Specialty Solutions has strengthened its cell and gene therapy capability with a coordinated suite of specialty distribution,…
Read More...

GSK announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of Benlysta (belimumab), a B-lymphocyte…
Read More...

The European Commission has granted marketing authorization for Zynquista (sotagliflozin)*, developed by Sanofi and Lexicon. Zynquista is now approved in the European Union, at…
Read More...

Regeneron Pharmaceuticals and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke and…
Read More...

Lonza announced the global availability of the world’s first fully automated and integrated plate-based PyroTec PRO Robotic Solution for endotoxin testing. Combining the speed and…
Read More...

Gilead Sciences announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once…
Read More...

ACADIA Pharmaceuticals Inc. announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate…
Read More...

Salix Pharmaceuticals and a wholly owned subsidiary of Bausch Health Companies Inc. announced that its affiliate has entered into an exclusive licensing agreement with Mitsubishi Tanabe…
Read More...

Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd., announced that they have entered into a…
Read More...

La Jolla Pharmaceutical Company announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the New Investigational Drug Product,…
Read More...

Forbius, a clinical-stage company that develops novel biologics for the treatment of fibrosis and cancer, announced that the first patient has been dosed in a Phase 1b trial assessing…
Read More...

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet…
Read More...

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), and Adagene Inc., an antibody…
Read More...

Velabs Therapeutics announced that it has entered into an agreement with Chiome Bioscience, Inc., Tokyo, to jointly discover modulatory and functional antibodies for one of Chiome’s…
Read More...

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe…
Read More...

Teva Pharmaceutical Industries Ltd. provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-specified…
Read More...

FSD Pharma Inc. and Prismic Pharmaceuticals Inc. announced that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD…
Read More...

UroGen Pharma Ltd. announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a…
Read More...

On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal…
Read More...